National trends in prescription drug expenditures and projections for 2021

Abstract

Purpose To report historical patterns of pharmaceutical expenditures, to identify factors that may influence future spending, and to predict growth in drug spending in 2021 in the United States, with a focus on the nonfederal hospital and clinic sectors. Methods Historical patterns were assessed by examining data on drug purchases from manufacturers using the IQVIA National Sales Perspectives database. Factors that may influence drug spending in hospitals and clinics in 2021 were reviewed—including new drug approvals, patent expirations, and potential new policies or legislation. Focused analyses were conducted for biosimilars, cancer drugs, generics, coronavirus disease 2019 (COVID-19) pandemic influence, and specialty drugs. For nonfederal hospitals, clinics, and overall (all sectors), estimates of growth of pharmaceutical expenditures in 2021 were based on a combination of quantitative analyses and expert opinion. Results In 2020, overall pharmaceutical expenditures in the United States grew 4.9% compared to 2019, for a total of $535.3 billion. Utilization (a 2.9% increase) and new drugs (a 1.8% increase) drove this increase, with price changes having minimal influence (a 0.3% increase). Adalimumab was the top drug in 2020, followed by apixaban and insulin glargine. Drug expenditures were $35.3 billion (a 4.6% decrease) and $98.4 billion (an 8.1% increase) in nonfederal hospitals and clinics, respectively. In clinics, growth was driven by new products and increased utilization, whereas in hospitals the decrease in expenditures was driven by reduced utilization. Several new drugs that will influence spending are expected to be approved in 2021. Specialty and cancer drugs will continue to drive expenditures along with the evolution of the COVID-19 pandemic. Conclusion For 2021, we expect overall prescription drug spending to rise by 4% to 6%, whereas in clinics and hospitals we anticipate increases of 7% to 9% and 3% to 5%, respectively, compared to 2020. These national estimates of future pharmaceutical expenditure growth may not be representative of any particular health system because of the myriad of local factors that influence actual spending.

Cost-Effectiveness Analysis of Direct Oral Anticoagulants Versus Vitamin K Antagonists for Venous Thromboembolism in China

“…API has a significant effect in reducing the risk of MB, and its safety and effectiveness are beyond those of similar drugs (Baber et al, 2014). But given the high price of API and the foreign patents that have not expired until 2023 (Tichy et al, 2021), the application scale of apixaban is still very rare in China (Yu et al, 2020). It is worth noting that with the launch of generic drugs in China, the reduction of the price of apixaban will lead to a more large-scale application, which probably makes it more economic.…”

The Effects of the National Centralized Drug Purchasing Pilot Program on Nucleos(t)ide Analogs in Shenzhen City: An Interrupted Time Series Analysis

“…Many countriesare facing the challenge of ever-increasing pharmaceutical expenditures all over the world. Using the IQVIA National Sales Perspectives database, total pharmaceutical expenditures in the United States were $535.3 billion in 2020, which grew 4.9% compared to 2019 ( 2 ). Medicine spending in Japan totaled $86 billion in 2018.…”

Cost sharing: implications of a well-intended benefits strategy

“…Prescription drug costs totaled $535.3 billion in 2020, an increase of 4.9% compared with 2019, and are projected to increase by 4%-6% in 2021. 1 To help mitigate these increases, several cost-containment strategies, such as closed formularies, prior authorization, step therapy protocols, and cost sharing, have been widely used by payers.…”

“…Recent changes in cost sharing could affect access to them. 4 The very idea of sharing health care costs with consumers so they have some "skin in the game" assumes that consumers (1) understand what cost sharing means and (2) are able to navigate through their pharmacy benefits, including cost-sharing scenarios, to make informed decisions. These assumptions bring to light the inherent complexities of benefit design; they can be very challenging for patients and lead to inadvertent consequences, the worst being not filling any medications altogether.…”